Home › Autoimmune Diseases › Massachusetts
Autoimmune Diseases clinical trials in Massachusetts
16 studies for Autoimmune Diseases are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Tufts Medical Center, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07621809Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Sep 17, 2026 · NCT06154252A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318The Mycophenolate Pregnancy Registry
- Quintiles Outcome, Cambridge
RecruitingObservational study
All ages · Women · Updated Sep 8, 2026 · NCT01733082RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- and 2 more
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 26, 2026 · NCT06121297Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder
- MGH Lurie Center for Autism, Lexington
RecruitingEarly phase 1
Ages 18 to 50 · Men · Updated Aug 19, 2026 · NCT06934915RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Beth Israel Deaconess Medical Center, Boston
- University of Massachusetts Chan Medical School, Worcester
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Aug 13, 2026 · NCT06359041A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- Boston Children's Cancer Center, Boston
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Aug 6, 2026 · NCT06056297Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1049, Foxborough
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Jul 30, 2026 · NCT07039916A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Brigham And Womens Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Jun 30, 2026 · NCT06201416A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Brigham and Women's Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 29, 2026 · NCT04422912Testimonials and Navigation in Rheumatology
- Brigham Women's Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
Recruiting
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06469788From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.